|
This information has been developed and provided by an independent third-party source. Merck & Co., Inc. does not endorse and is not responsible for the accuracy of the content, or for practices or
standards of non-Merck sources.
Pronunciation
(ter AY zoe sin)
Index Terms
Generic Available
Yes
Canadian Brand Names
Pharmacologic Category
Pharmacologic Category Synonyms
Use: Labeled Indications
Management of mild-to-moderate hypertension; alone or in combination with other agents such as diuretics or beta-blockers; benign prostate hyperplasia (BPH)
Use: Unlabeled/Investigational
Pediatric hypertension
Pregnancy Risk Factor
C
Pregnancy Considerations
Teratogenic effects have not been observed in animal studies. Decreased fetal weight and increased risk of fetal mortality were noted in some animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.
Lactation
Excretion in breast milk unknown/use caution
Contraindications
Hypersensitivity to terazosin or any component of the formulation
Warnings/Precautions
Concerns related to adverse effects:
• Angina: Discontinue if symptoms of angina occur or worsen.
• Floppy iris syndrome: Intraoperative floppy iris syndrome has been observed in cataract surgery patients who were on or were previously treated with alpha1-blockers; causality has not been established and there appears to be no benefit in discontinuing alpha-blocker therapy prior to surgery.
• Orthostatic hypotension/syncope: May cause significant orthostatic hypotension and syncope, especially with first dose; anticipate a similar effect if therapy is interrupted for a few days, if dosage is rapidly increased, or if another antihypertensive drug (particularly vasodilators) or a PDE-5 inhibitor is introduced. Patients should be cautioned about performing hazardous tasks when starting new therapy or adjusting dosage upward.
• Priapism: Priapism has been associated with use (rarely).
Disease-related concerns:
• Prostate cancer: It is recommended to rule out prostatic carcinoma before beginning therapy.
Adverse Reactions
>10%:
Central nervous system: Dizziness (9% to 19%)
Neuromuscular & skeletal: Muscle weakness (7% to 11%)
1% to 10%:
Cardiovascular: Peripheral edema (1% to 6%), orthostatic hypotension (1% to 4%), palpitation (?4%), tachycardia (?2%), syncope (?1%)
Central nervous system: Somnolence (4% to 5%), vertigo (1%)
Gastrointestinal: Nausea (2% to 4%)
Genitourinary: Impotence (?2%), libido decreased (?1%)
Neuromuscular & skeletal: Extremity pain (?4%), paresthesia (?3%), back pain (?2%)
Ocular: Blurred vision (?2%)
Respiratory: Nasal congestion (2% to 6%), dyspnea (2% to 3%), sinusitis (?3%)
<1%, postmarketing, and/or case reports: Abdominal pain, abnormal vision, allergic reactions, anaphylaxis, anxiety, arrhythmia, arthralgia, arthritis, atrial fibrillation, bronchitis, chest pain, conjunctivitis, constipation, cough, diaphoresis, diarrhea, dyspepsia, epistaxis, facial edema, fever, flatulence, flu-like syndrome, gout, insomnia, intraoperative floppy iris syndrome (IFIS), joint disorder, myalgia, neck pain, pharyngitis, polyuria, priapism, pruritus, rash, rhinitis, shoulder pain, thrombocytopenia, tinnitus, urinary incontinence, urinary tract infection, vasodilation, vomiting, xerostomia
Drug Interactions
Alfuzosin: Alpha1-Blockers may enhance the antihypertensive effect of Alfuzosin. Risk of orthostatic hypotension or syncope may be increased. Alfuzosin may enhance the antihypertensive effect of Alpha1-Blockers. Risk X: Avoid combination
Amifostine: Antihypertensives may enhance the hypotensive effect of Amifostine. Management: When amifostine is used at chemotherapy doses, antihypertensive medications should be withheld for 24 hours prior to amifostine administration. If antihypertensive therapy can not be withheld, amifostine should not be administered. Risk D: Consider therapy modification
Antihypertensives: May enhance the hypotensive effect of other Antihypertensives. Risk C: Monitor therapy
Beta-Blockers: May enhance the orthostatic effect of Alpha1-Blockers. The risk associated with ophthalmic products is probably less than systemic products. Exceptions: Levobunolol; Metipranolol. Risk D: Consider therapy modification
Calcium Channel Blockers: Alpha1-Blockers may enhance the hypotensive effect of Calcium Channel Blockers. Risk C: Monitor therapy
Diazoxide: May enhance the hypotensive effect of Antihypertensives. Risk C: Monitor therapy
Herbs (Hypertensive Properties): May diminish the antihypertensive effect of Antihypertensives. Risk C: Monitor therapy
Herbs (Hypotensive Properties): May enhance the hypotensive effect of Antihypertensives. Risk C: Monitor therapy
Hypotensive Agents: May enhance the adverse/toxic effect of other Hypotensive Agents. Risk C: Monitor therapy
MAO Inhibitors: May enhance the orthostatic effect of Orthostasis Producing Agents. Risk C: Monitor therapy
Methylphenidate: May diminish the antihypertensive effect of Antihypertensives. Risk C: Monitor therapy
Pentoxifylline: May enhance the hypotensive effect of Antihypertensives. Risk C: Monitor therapy
Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Alpha1-Blockers. Management: Ensure patient is stable on alpha 1 blocker before starting PDE5 inhibitor; initiate PDE5 inhibitor at lowest possible dose. If patient stable on PDE5 inhibitor, initiate alpha 1 blocker at lowest dose. Risk D: Consider therapy modification
Prostacyclin Analogues: May enhance the hypotensive effect of Antihypertensives. Risk C: Monitor therapy
RiTUXimab: Antihypertensives may enhance the hypotensive effect of RiTUXimab. Risk D: Consider therapy modification
Silodosin: Alpha1-Blockers may enhance the adverse/toxic effect of Silodosin. Of particular concern are the risk of postural hypotension, syncope, and/or hypotension. Silodosin may enhance the hypotensive effect of Alpha1-Blockers. Of particular concern are the risk of postural hypotension, syncope, and/or hypotension. Risk X: Avoid combination
Tamsulosin: Alpha1-Blockers may enhance the antihypertensive effect of Tamsulosin. Risk of orthostatic hypotension or syncope may be increased. Tamsulosin may enhance the antihypertensive effect of Alpha1-Blockers. Risk X: Avoid combination
Yohimbine: May diminish the antihypertensive effect of Antihypertensives. Risk C: Monitor therapy
Ethanol/Nutrition/Herb Interactions
Herb/Nutraceutical: Avoid dong quai if using for hypertension (has estrogenic activity). Avoid ephedra, yohimbe, ginseng (may worsen hypertension). Avoid saw palmetto. Avoid garlic (may have increased antihypertensive effect).
Storage
Store below 30°C (86°F).
Mechanism of Action
Alpha1-specific blocking agent with minimal alpha2 effects; this allows peripheral postsynaptic blockade, with the resultant decrease in arterial tone, while preserving the negative feedback loop which is mediated by the peripheral presynaptic alpha2-receptors; terazosin relaxes the smooth muscle of the bladder neck, thus reducing bladder outlet obstruction
Pharmacodynamics/Kinetics
Onset of action: 1-2 hours
Absorption: Rapid and complete
Protein binding: 90% to 95%
Metabolism: Hepatic; minimal first-pass
Half-life elimination: ~12 hours
Time to peak, serum: ~1 hour
Excretion: Feces (~60%, ~20% as unchanged drug); urine (~40%, ~10% as unchanged drug)
Dosage
Oral:
Hypertension:
Children (unlabeled use): Initial: 1 mg once daily; gradually increase dose as necessary, up to maximum of 20 mg/day
Adults: Initial: 1 mg at bedtime; slowly increase dose to achieve desired blood pressure, up to 20 mg/day; usual dose range (JNC 7): 1-20 mg once daily
Benign prostatic hyperplasia: Adults: Initial: 1 mg at bedtime; thereafter, titrate upwards, if needed, over several weeks, balancing therapeutic benefit with terazosin-induced postural hypotension; most patients require 10 mg day; if no response after 4-6 weeks of 10 mg/day, may increase to 20 mg/day
Concurrent use with a diuretic or other antihypertensive agent (especially verapamil): Dosage reduction may be needed when adding
Concurrent use with PDE-5 inhibitors: Initiate PDE-5 inhibitor therapy at the lowest dose due to additive orthostatic and blood pressure lowering effects
Note: If drug is discontinued for greater than several days, consider beginning with initial dose and retitrate as needed; dosage may be given on a twice daily regimen if response is diminished at 24 hours and hypotension is observed at 2-4 hours following a dose.
Administration: Oral
Administered without regard to meals at the same time each day.
Monitoring Parameters
Standing and sitting/supine blood pressure, especially following the initial dose at 2-4 hours following the dose and thereafter at the trough point to ensure adequate control throughout the dosing interval; urinary symptoms
Dietary Considerations
May be taken without regard to meals at the same time each day.
Patient Education
Do not take any new medication during therapy unless approved by prescriber. Take as directed; at bedtime. Do not skip dose or discontinue without consulting prescriber. Follow recommended diet and exercise program. May cause drowsiness, dizziness, or impaired judgment (use caution when driving or engaging in tasks that require alertness until response to drug is known); postural hypotension (use caution when rising from sitting or lying position or when climbing stairs); dry mouth or nausea (frequent mouth care or sucking lozenges may help); urinary incontinence (void before taking medication); or sexual dysfunction (reversible, may resolve with continued use). Report altered CNS status (eg, fatigue, lethargy, confusion, nervousness); sudden weight gain (weigh yourself in the same clothes at the same time of day once a week); unusual or persistent swelling of ankles, feet, or extremities; palpitations or rapid heartbeat; respiratory difficulty; muscle weakness; or other persistent side effects. Pregnancy/breast-feeding precautions: Inform prescriber if you are or intend to become pregnant. Consult prescriber if breast-feeding.
Geriatric Considerations
Adverse reactions such as dry mouth and urinary problems can be particularly bothersome in the elderly.
Cardiovascular Considerations
An alpha1-blocker may be used in combination with other agents for the treatment of hypertension or alone in select patients who fail to respond or have contraindications to other agents. Patients with BPH may derive an extra benefit from therapy. Recently, the doxazosin treatment arm of ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) was prematurely stopped due to a significantly higher incidence (25%) of cardiovascular events (particularly heart failure events), compared to the diuretic (chlorthalidone) treatment arm. This unfavorable difference was also present when doxazosin was compared to the amlodipine and lisinopril treatment arms. This study does not address cardiovascular outcomes when doxazosin is combined with other antihypertensive medications. Consideration should be given to the ALLHAT results when considering the use of an alpha1-blocker for treatment of hypertension.
Dental Health: Effects on Dental Treatment
Key adverse event(s) related to dental treatment: Xerostomia (normal salivary flow resumes upon discontinuation) and orthostatic hypotension.
Dental Health: Vasoconstrictor/Local Anesthetic Precautions
No information available to require special precautions
Mental Health: Effects on Mental Status
Dizziness is common; may cause drowsiness or nervousness; may rarely cause insomnia or depression
Mental Health: Effects on Psychiatric Treatment
None reported
Nursing: Physical Assessment/Monitoring
Assess potential for interactions with other pharmacological agents and herbal products patient may be taking (especially anything that may decrease antihypertensive response [NSAIDS, ephedra, yohimbe, ginseng] or increase hypotensive effect [beta-blockers, diuretics, ACE inhibitors]). Assess therapeutic effectiveness (blood pressure) and adverse reactions (eg, hypotension, dizziness, somnolence, impotence) at beginning of therapy and on a regular basis with long-term therapy. When discontinuing, dose should be tapered and blood pressure monitored closely. Teach patient proper use, possible side effects/appropriate interventions, and adverse symptoms to report.
Dosage Forms
Excipient information presented when available (limited, particularly for generics); consult specific product labeling.
Capsule: 1 mg, 2 mg, 5 mg, 10 mg
Pricing: U.S. (www.drugstore.com)
Capsules (Terazosin HCl)
1 mg (30): $14.45
2 mg (30): $13.99
5 mg (30): $13.99
10 mg (30): $13.99
References
Chobanian AV, Bakris GL, Black HR, et al, “The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report,” JAMA, 2003, 289(19):2560-71.
"Major Cardiovascular Events in Hypertensive Patients Randomized to Doxazosin vs Chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). ALLHAT Collaborative Research Group," JAMA, 2000, 283(15):1967-75.
National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents, “The Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents,” Pediatrics, 2004, 114(2 Suppl):555-76.
International Brand Names
Lexi-Comp.com
Last full review/revision November 2009
|
